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Table 2. AFSS scores by SAF classiﬁcation and the correlation between AFSS
outcome scores and SAF classiﬁcation
SAF 0 SAF 1 SAF 2 SAF 3 SAF 4 p value
Correlation
coefﬁcient
(p value)
Total AF burden
(3-30){
5.75.1 9.25.0 15.24.6 17.63.8 21.44.7 < 0.001 0.75
(<0.001)
Symptom
severity
(0-35){
3.34.0 4.25.2 9.94.2 15.25.0 23.6.6.8 <0.001 0.79
(<0.001)
Health care
utilization:
Cardioversion* 0.41.0 0.20.5 0.20.5 0.51.4 0.50.7 0.80 0.08 (0.40)
Emergency
room
visit*
0.30.5 0.51.1 0.61.0 1.31.6 2.51.9 <0.001 0.4
(<0.001)
Hospitalization* 0.30.5 0.50.8 0.50.6 0.71.1 1.41.6 0.08 0.2 (0.05)
Specialist visit* 1.71.5 1.81.8 2.82.6 2.22.1 2.71.7 0.47 0.18 (0.16)
Data are presented as meanstandart deviation. A correlation coeffcient of >0.6
indicates strong correlation. {The numbers indicate range of scores. *The score of the
items in the health care utilization subscale ranges from 0-7. Increasing scores indicate
increasing symptoms. AFSS: Atrial Fibrillation Severity Scale SAF: Severity in Atrial Fibrillation
class
Table 3. Internal consistency of the three domains of the AFSS
Internal consistency (Conbach a)
Total AF burden 0.85
Symptom severity 0.90
Health care utilization 0.67
AFSS: AF severity scale AF: atrial ﬁbrillation
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Table 1. AFSS outcome scores by EHRA classiﬁcation and the correlation
between the AFSS outcome scores and EHRA classiﬁcation
EHRA 1 EHRA 2 EHRA 3 EHRA 4 p value
Correlation
coefﬁcient
(p value)
Total AF burden
(range:3-30)
7.15.2 14.45.3 17.04.6 22.63.4 < 0.001 0.7 (<0.001)
Symptom severity
(range 0-35)
3.64.7 8.85.8 17.76.6 23.87.4 < 0.001 0.7 (<0.001)
Health care
utilization:
Cardioversion (0-7)
*
0.20.6 0.30.84 0.41.2 0.70.8 0.5 0.1 (0.09)
Emergency room
visit
(0-7)*
0.20.4 0.71.1 1.71.8 2.82.0 <0.001 0.4 (<0.001)
Hospitalization (0-
7)*
0.20.4 0.60.8 1.01.1 1.81.6 0.001 0.4 (<0.001)
Specialist visit (0-
7)*
1.51.5 2.52.3 2.52.0 2.81.8 0.2 0.2 (0.07)
Data are presented as meanstandard deviation. *The numbers indicate the range of scores.
A correlation coefﬁcient of > 0.6 indicate strong correlation. Increasing scores indicate
increasing symptoms and severity. AFSS: Atrial Fibrillation Severity Scale EHRA:European
Heart Rhythm Association class
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Objective: This study aimed at the assessment of the clinical approach to AF in
the older population and the consistency with the guidelines based on the records of
the multicenter, prospective AFTER (Atrial Fibrillation in Turkey: Epidemiologic
Registry) study.
Methods: 2242 consecutive patients admitted to the cardiology outpatient clinics of
17 different tertiary health care centers with at least one AF attack determined on
electrocardiographic examination, were included in the study. Among the patients
included in the study, 631 individuals aged 75 years and older were analyzed.
Results: The mean age of the patients was determined as 80.34.2 years. The most
frequent type of AF in geriatric population was the persistent- permanent type with
a percentage of 88%. 60% of the patients with AF were female. Hypertension was the
most common co-morbidity in patients with AF (76%). While in 16% of patients
a history of stroke, transient ischemic attack or systemic thromboembolism was
present, a history of bleeding was present in 14% of the patients. 37% of the patients
were on warfarin treatment and 60% of the patients were on aspirin treatment. In 38 %
of the patients who were on oral anticoagulant treatment, INR level was in the
effective range.
Conclusion: The rate of anticoagulant use in the elderly with AF was 37% and
considering the reason of this situation was the medication not being prescribed by the
physician, one should pay more attention particularly in the ﬁeld of treatment.
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Introduction: Since transition disease has become a reality with the aging of the
population, non-valvular AF appears as a new challenge in the scope of cardiology.
There are two strategies in the treatment of atrial ﬁbrillation. One of them is car-
dioversion and maintenance of sinus rhythm with antiarrhythmic drugs; the other one
is respect of AF and treatment with rate control drugs.
The two strategies were widely compared in the Afﬁrm Study Without superiority
of any of them. However, with a focus on the population studied in Afﬁrm, we notice
that it concerned old population at high risk of Stroke.
The aim of our study is then to compare the two strategies from another angle by
targeting a population of younger and more active patients with AF.
Methods: We randomly assigned, in a prospective open-label study, 266 eligible
patients with non- valvular AF, average age 52,419,6 years, 174 men (65,4 %,sex
ratio 1,89), to undergo a rhythm control (R¼131 patients) or a rate Control (F¼131
pts) strategy.
The average follow -up (FU) was 27,18 months with 4 patients lost of view.
15 pts (8 and 7) were concerned by cross over from one strategy to the other.
Results: 240 pts (90%) pts were symptomatic. AF was paroxystic in 97 pts (36%),
persistent in 61pts (23%) and permanent in 108pts (41%). 203 pts had comorbidities
particularly hypertension in 142 (53%) and diabetes in 34 (13%). Isolated AF was
present in 63pts (24%).219 pts (82%) were at low thromboembolic risk with
a CHADS2 score 1. The hemodynamic status was favorable with an average LVEF
of 64%.
There were fewer events in the R arm than in the F one, appearing late during FU
but the difference wasn't statistically signiﬁcant. There was no signiﬁcant difference in
survival without heart failure or ischemic stroke, respectively 83.8% [CI: 68.5- 100]
and 56.6% [36.4-88], p¼0.43.
Discussion-Conclusion: These results can be explained by the young age of the
population with a low risk in which the events are rare and late in a chronic disease
that requires treatment and long term follow up. For more than 2 years FU, superiority
of rhythm control over rate control wasn't demonstrated despite the patients’ proﬁle
that seemed to be favorable. However, given the shape of the survival curves, we can
anticipate a superiority of rhythm control in the long term.ol 62/18/Suppl C j October 26–29, 2013 j TSC Abstracts/ORALS
The Beta-Fibrinogen 455 G/A Polymorphism genotype and allel frequencies
AF patients with
Ischemic Stroke
(n:70)
Control
(n:65)
n: % n: %
GG genotype 23 32.9 36 55.4 0.008
GA genotype 27 38.6 25 38.5 0.990
AA genotype 20 28.6 4 6.2 0.001
GA+ AA genotypes
(Dominant genetic
model)
47 67.1 29 44.6 0.008
A allel 67 47.8 33 25.3 0.001
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Introduction: Atrial ﬁbrillation is the most common cardiac arrhythmia increasing
the risk of stroke and death. Inﬂammation is an important factor involved in the
initiation, maintenance and recurrence of AF and The abnormal inﬂammatory state
may also cause a prothrombotic state resulting thromboembolism. In the present study
we aim to investigate whether serum levels of galectin-3, Matrix Metalloproteinase 9
(MMP-9) and Procollagen III N-Terminal Propeptide (PIIINP),Human Lipocalin-2/
NGAL and NLR differ in patients with AF compared to patients with sinus rhythm in
the guidance of serum levels of MMP-9 and Hs-CRP. We also evaluated associations
of these markers with atrial structural remodeling which was interpreted by measuring
the left atrial volume index.
Methods: The study population included 85 patients who were seen in our outpa-
tient clinic between March 2012 and January 2012. 52 patients who diagnosed with
non-valvular AF recruited into AF group. End-stage hepatic or renal disease,
malignancy, any prior blood transfusions, carotid artery disease, prior transient
ischemic attack, ischemic or hemorrhagical stroke and oral anticoagulant usage were
exclusion criteria in our study. 35 age-matched patients with sinus rhythm recruited
into control group. Serum levels of Galectin-3, Matrix Metalloproteinase 9 (MMP-9)
and Procollagen III N-Terminal Propeptide (PIIINP) were measured by using
a commercial enzyme-linked immunoassay kits and each assay was carried out in
duplicate. Galectin-3, NGAL, MMP-9 and PIIINP levels were measured by using
sandwich ELISA (Human Galectin-3 ELISA kit, eBioscience; Lipocalin-2/NGAL
Elisa kit, BioVendor Research and Diagnostic Products; Human Matrix Metal-
loproteinase 9, Bio-Medical Assay; Human Procollagen III N-Terminal Propeptid,
Bio-Medical Assay).
Results: There were signiﬁcant differences between the groups in terms of
inﬂammatory and remodeling markers except NGAL levels. We showed signiﬁ-
cantly higher levels of Galectin-3, MMP-9, PIIINP in in NVAF group compared to
control group (1166 pg/ml (1126-1204) & 1204 pg/ml (1166-1362) p¼0.001
Mann-Whitney U test, 14688 pg/ml & 429302 pg/ml p<0.0001 Student-t test,
and 1426Student-t test respectively). Hs1230 pg/ml & 65904594 pg/ml
p<0.0001 -Crp and NLR level were also higher in NVAF (2.11.0 & 2.71.1
p¼0.02 Student-t test and 4.21.9 mg/L & 6.04.7 mg/L p¼0.04 Student-t test,
respectively).
In correlation analyses, NLR showed quite signiﬁcant correlation with LAVi
whereas Hs-CRP did not (p¼0.007 r¼0.247, pearson test & p¼0.808 r¼0.025,
pearson test,respectively). Moreover, Galectin-3, MMP-9, and PIIINP had strong
positive correlation with LAVi (p¼0.021 r¼640, spearman test & p¼0.004 r¼0.319
pearson test, & p¼0.004 r¼0.325 pearson test,respectively).
Conclusion: As a result of this data we suggest that galectin-3 and PIIINP can be used
as novel targets in AF patients in order to decrease degree of ﬁbro-inﬂammation in
the atria.JACC Vol 62/18/Suppl C j October 26–29, 2013 j TSC Abstracts/ORAOP-151
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Background: Atrial ﬁbrillation (AF) is the most commonly observed arrhythmia in
clinical practice and associated with increased cardiovascular morbidity and
mortality. Compared to healthy population, nonvalvular AF has a 2-7 fold
increased risk of ischemic stroke. The mechanisms of thrombus formation in AF
are still investigated. Fibrinogen plays an active role during the coagulation
process. Increased plasma ﬁbrinogen levels were shown to be associated with
the coronary heart disease, peripheral artery disease and venous thrombosis.
Beta-ﬁbrinogen 455 G/A polymorphism is a gene mutation that may lead to
alterations in the activity of ﬁbrinogen. We wanted to investigate Beta-ﬁbrinogen
455 G/A polymorphism in patients with AF who have had a stroke than in healthy
controls.
Methods: The Beta-ﬁbrinogen 455 G/A polymorphism was analysed in 70 patients
with AF who have had a stroke 65 healthy individuals matched for age, race and sex.
Because ethnic differences have been reported for Beta-ﬁbrinogen 455 G/A poly-
morphism. The Beta-ﬁbrinogen 455 G/A gene polymorphism was identiﬁed by
polymerase chain reaction (PCR) method. Distribution of the Beta-ﬁbrinogen 455 G/A
gene polymorphism alles (allel G, allel A) genotypes (Normal (GG) genotype,
heterozygous (GA) or homozygous (AA) mutant genotype) were identiﬁed in study
population. Demographic characteristics and risk factors for AF and stroke were
evaluated in the study groups.
Results: There was no signiﬁcant difference with respect to age and gender between
groups. Genotype and allel distribution of nonvalvular AF patients with ischemic
stroke and control groups shown in the table. The frequency of GG genotype of Beta-
ﬁbrinogen 455 G/A polymorphism was signiﬁcantly lower in patients with AF who
have had a stroke group compared with control group (p<0,05). The frequency of GA
heterozygous genotype was similar between groups. The frequency of AA homozy-
gous mutant genotype of Beta-ﬁbrinogen 455 G/A polymorphism was signiﬁcantly
higher in patients with AF who have had a stroke group compared with control group
(p<0,05). Between the two groups were compared according to the dominant genetic
model (GA+AA vs. GG), The number of patients carrying at least one A mutant
allele (GA+AA) were signiﬁcantly higher in patients with AF who have had a stroke
group than controls (p<0,05). With respect to allelic distribution (G vs A, additive
model), the frequency of the A mutant allele was signiﬁcantly higher in CAE patients
(p<0,05).
Conclusions: In this study, we found that the frequency of b-ﬁbrinogen 455 G/A gene
polymorphism was higher in patients with AF who have had a stroke group compared
to control subject. However, further large-sized studies are required for determining
relationship between b-ﬁbrinogen 455 G/A gene polymorphisms and patients with AF
who have had a stroke group.LS C67
